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ABSTRACT 25 
 26 
Background: To date, our programme of systematic reviews has assessed randomised controlled trials 27 
(RCTs) of individualised homeopathy separately for risk of bias (RoB) and for model validity of 28 
homeopathic treatment (MVHT).  Objectives: The purpose of the present paper was to bring together 29 
our published RoB and MVHT findings and, using an approach based on GRADE methods, to merge the 30 
quality appraisals of these same RCTs, examining the impact on meta-analysis results.  Design: 31 
Systematic review with meta-analysis.  Methods: As previously, 31 papers (reporting a total of 32 32 
RCTs) were eligible for systematic review and were the subject of study.  Main outcome measures: For 33 
each trial, the separate ratings for RoB and MVHT were merged to obtain a single overall quality 34 
designation (‘high’, ‘moderate, ‘low’, ‘very low’), based on the GRADE principle of 'downgrading'.  35 
Results: Merging the assessment of MVHT and RoB identified three trials of ‘high quality’, eight of 36 
‘moderate quality’, 18 of ‘low quality’ and three of ‘very low quality’.  There was no association 37 
between a trial’s MVHT and its RoB or its direction of treatment effect (P>0.05).  The three ‘high 38 
quality’ trials were those already labelled ‘reliable evidence’ based on RoB, and so no change was found 39 
in meta-analysis based on best-quality evidence: a small, statistically significant, effect favouring 40 
homeopathy.  Conclusion: Accommodating MVHT in overall quality designation of RCTs has not 41 
modified our pre-existing conclusion that the medicines prescribed in individualised homeopathy may 42 
have small, specific, treatment effects. 43 
 44 
Abstract word count: 239 45 
 46 
 47 
 48 
Key words: Individualised homeopathy; Meta-analysis; Model validity; Randomised placebo-controlled 49 
trials; Systematic review50 
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BACKGROUND 51 
 52 
Our programme of systematic reviews of randomised controlled trials (RCTs) in homeopathy is focusing 53 
its quality assessment both on internal validity (risk of bias, RoB) and on model validity (MV) [1]. Our 54 
earlier work on RoB showed that, of 32 eligible RCTs of individualised homeopathy, none was totally 55 
free from potential bias, though three comprised ‘reliable evidence’ [2].  As regards MV of the same 32 56 
RCTs, 19 were considered acceptable, nine uncertain, and four inadequate [3].  Sensitivity analysis 57 
reflecting the ‘reliable evidence’ produced cautious support for the hypothesis that the effect of the 58 
individualised homeopathic intervention is distinguishable from the same approach using placebos [2]. 59 
 60 
The purpose of the present paper is to merge together our previously published RoB and MV findings 61 
[2, 3] and, using an approach based on the GRADE method [4], to establish an overall quality 62 
designation for each of the 32 RCTs and to examine its impact on the sensitivity analysis findings.  63 
Inter-relationships between RoB, MV and direction of treatment effect are also explored. 64 
 65 
METHODS 66 
 67 
Inclusion criteria for RCTs 68 
 69 
We previously applied the appraisal methods for RoB and for model validity of homeopathic treatment 70 
(MVHT), as described [1, 3, 4, 5], to papers that reported peer-reviewed, randomised, placebo-71 
controlled trials of individualised homeopathy, published up to the end of 2013.  Through formal 72 
literature search methods, and after application of defined exclusion criteria, 31 papers (reporting a total 73 
of 32 RCTs) were found to be eligible for systematic review [2]. 74 
 75 
Assessment of model validity of homeopathic treatment 76 
 77 
For each trial, the domains for MVHT assessment are summarised as follows [3, 5]: 78 
 79 
Domain I (Rationale): Would a significant body of accredited homeopaths support the rationale 80 
for the intervention used in the study? 81 
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Domain II (Principles): Is the specific intervention used consistent with homeopathic 82 
principles? 83 
Domain III (Practitioner): Does the study have suitably qualified and experienced homeopathic 84 
practitioner input? 85 
Domain IV (Outcome measure): Does the main outcome measure reflect the main effect 86 
expected of the intervention used? 87 
Domain V (Outcome sensitivity): Is the main outcome measure capable of detecting change? 88 
Domain VI (Follow-up): Is the length of follow-up for the main outcome measure appropriate to 89 
detect the intended effect of the intervention? 90 
 91 
The overall MVHT classification per trial was assigned as follows [3, 5]: 92 
Acceptable MVHT: Acceptable rationale (domain I) and principles (domain II); 93 
acceptable outcome measure (domain IV) and sensitivity (domain V); not ‘inadequate 94 
MVHT’ in either of the other two domains (III, VI). 95 
Uncertain MVHT: ‘Unclear’ for at least one of the four key domains (I, II, IV, V); not 96 
‘inadequate MVHT’ for either of the other domains (III, VI). 97 
Inadequate MVHT: ‘Unacceptable MVHT’ for any one or more domains. 98 
 99 
Assessment of risk of bias 100 
 101 
 For each trial, the domains for RoB are summarised as follows [6]: 102 
 103 
Domain I: Sequence generation. 104 
Domain II: Allocation concealment used to implement the random sequence. 105 
Domain IIIa: Blinding of participants and study personnel. 106 
Domain IIIb: Blinding of outcome assessors. 107 
Domain IV: Incomplete outcome data. 108 
Domain V: Selective outcome reporting. 109 
Domain VI: Other sources of bias. 110 
 111 
The overall RoB classification per trial was assigned as follows [2]: 112 
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• Low risk of bias overall: Low risk of bias for each of the seven domains above 113 
(designated reliable evidence). 114 
• Uncertain risk of bias overall: Unclear RoB for at least one domain; low RoB for all 115 
other domains. 116 
o A trial was designated reliable evidence if the uncertainty in its risk of bias was 117 
for one of domains IV, V or VI only (and free of overt bias for each of domains I, 118 
II, IIIA and IIIB). 119 
• High risk of bias overall: High RoB for any one or more domains. 120 
 121 
Merging RoB and MVHT into single overall quality designation 122 
 123 
Our separate ratings for RoB [2] and MVHT [3] were merged to obtain a single overall designation, 124 
based on the GRADE principle of 'downgrading' trials with lesser degrees of quality [4].  For the current 125 
study, a trial was downgraded using the specific approach shown in Table 1. 126 
 127 
Direction of treatment effect 128 
 129 
For each trial, the ‘direction of treatment effect’ was described statistically as ‘favouring homeopathy’ or 130 
‘favouring placebo’, as per the findings of our previous meta-analysis [2].  These descriptions reflect, 131 
respectively, a mean odds ratio (OR) greater than or less than 1.00; statistical significance at P < 0.05 132 
was attributed if the 95% confidence interval (CI) did not overlap the value OR = 1.00. 133 
 134 
Inter-relationship between trial attributes 135 
 136 
We planned to use the Chi-squared (Ç2) test to compare frequencies of observations, and thus the inter-137 
relationships between RoB and MVHT and direction of treatment effect. Fisher’s Exact test was 138 
preferred when expected frequency was less than 5 in at least one cell of a given frequency table. 139 
 140 
Sensitivity analysis 141 
 142 
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Sensitivity analysis, using methods corresponding to those in our associated paper [2], examined the 143 
impact on the pooled OR of trials’ overall quality designation. 144 
 145 
RESULTS 146 
 147 
MVHT overall 148 
 149 
As previously reported [3], there were 19 trials with acceptable MVHT, nine with uncertain MVHT, and 150 
four with inadequate MVHT (Table 2). 151 
 152 
RoB overall 153 
 154 
No trials had low RoB [2].  There were 12 trials with uncertain RoB (three of which were designated 155 
‘reliable evidence’: study numbers A5, A19 and A20 in Table 2), and 20 with high RoB (Table 2). 156 
 157 
Overall quality designation (Table 2) 158 
 159 
Each of the three trials assessed as ‘reliable evidence’ [2] had acceptable MVHT [3]: these three trials 160 
were therefore designated ‘high quality’, and so remain the top-ranked RCTs of individualised 161 
homeopathic treatment.  Of the other nine trials that had uncertain RoB, eight had acceptable or 162 
uncertain MVHT, and one had unacceptable MVHT; with appropriate downgrading by quality, these 163 
trials were designated respectively as ‘moderate quality’ (N=8) and ‘low quality’ (N=1).  Thus, 11 RCTs 164 
were not importantly deficient in quality overall.  Of the remaining 21 RCTs, 18 were designated ‘low 165 
quality’ and three as ‘very low quality’. 166 
 167 
Direction of treatment effect (Table 2) 168 
 169 
Only 22 of the 32 trials had data that were extractable for meta-analysis [2].  Fifteen of these 22 had a 170 
direction of treatment effect favouring homeopathy; seven favoured placebo.   171 
 172 
Inter-relationship between trial attributes 173 
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 174 
MVHT and risk of bias 175 
 176 
There was no evidence to support an association between MVHT and RoB (Fisher’s Exact P = 0.882) – 177 
Table 3. 178 
 179 
MVHT and direction of treatment effect 180 
 181 
There was no evidence to support an association between a trial’s MVHT and its direction of treatment 182 
effect (Fisher’s Exact P = 0.381) – Table 4. 183 
 184 
Risk of bias and direction of treatment effect 185 
 186 
There was no evidence to support an association between a trial’s RoB and its direction of treatment 187 
effect (Fisher’s Exact P = 0.690) – Table 5. 188 
 189 
Sensitivity analysis 190 
 191 
Table 6 shows the effect of removing data by trials’ overall quality designation: i.e. removing 11 ‘low-192 
quality’ RCTs, then eight ‘moderate-quality’ RCTs.  The pooled OR showed a small, statistically 193 
significant, effect in favour of homeopathy for each set of N trials, including for the final N=3 RCTs 194 
(those designated ‘high quality’). 195 
 196 
DISCUSSION 197 
 198 
Our study has successfully brought together RoB and MVHT assessments using an approach based on 199 
the GRADE system of ‘downgrading’ lesser-quality trials.  Merging together the two quality attributes 200 
revealed 11 out of 32 trials with either high or moderate quality overall.  Those with ‘high quality’ are 201 
the three RCTs that comprise ‘reliable evidence’ based on RoB [2] and that also possess acceptable 202 
MVHT [3].  The main finding from our prior meta-analysis [2] has therefore not been modified by 203 
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accommodating MVHT: there is cautious support for the hypothesis that the effect of the individualised 204 
homeopathic intervention is distinguishable from the same approach using placebos. 205 
 206 
The trials with ‘moderate quality’ overall are eight of nine RCTs that comprise uncertain risk of bias [2].  207 
The MVHT-deficient trial with uncertain risk of bias (study number A25) displayed a direction of 208 
treatment effect favouring homeopathy.n  There was no trial that had inadequate MVHT and whose 209 
direction of effect favoured placebo, though other MVHT-deficient trials did not contain extractable data 210 
for meta-analysis, preventing their quantitative examination. 211 
 212 
It is notable that many trials with acceptable MVHT had high RoB.  Indeed, high RoB comprised the 213 
major proportion of trials in each class of MVHT (Table 3), though no statistically significant inter-214 
relationships were evident.  The proportion of trials with a given direction of treatment effect appeared 215 
to be little affected by RoB and/or MVHT; the total number of trials is too small, however, to enable 216 
definitive conclusions.  The absence of such relationships is supported by our sensitivity analysis, which 217 
showed a small, significant treatment, effect toward homeopathy irrespective of the quality of trial 218 
retained in analysis.  To date, therefore, there is no evidence that the MVHT method merely intercepts 219 
those trials with evidence against homeopathy, as has been suggested recently [7]. 220 
 221 
It remains a matter of concern to homeopathy that two-thirds (21 of 32) RCTs of individualised 222 
homeopathic treatment have importantly deficient quality overall.  Although RCTs in conventional 223 
medicine have not benefitted from a two-attribute appraisal of quality such as ours, systematic reviews 224 
that solely examined RoB have frequently expressed concern about the insufficient quantity of evidence 225 
available to answer a given research question [8].  It is reassuring, at least, that so few of our 32 226 
homeopathy trials have overtly inadequate MVHT [3] and that the majority thus seem to involve 227 
‘genuine homeopathy’ [9].  It is unknown to what extent model validity might impact on the 228 
interpretation of RCT findings in other branches of Complementary/Alternative Medicine (CAM); our 229 
MVHT method seems adaptable to addressing that question, as previously proposed [5].  It is also 230 
                                                 
n Additional sensitivity analysis based on the original authors’ selection of ‘primary outcome measure’ has identified 
potentially a fourth RCT in the category ‘Uncertain RoB – reliable evidence’: http://www.britishhomeopathic.org/wp-
content/uploads/2015/01/BHA-16-Jan-2015.pdf.  That RCT (White 2003: study number A39 in tabulated material) would 
then be upgraded in our current rank order classification – see Supplementary File 1 – as a second trial that is MVHT-
deficient and with uncertain risk of bias, displaying a direction of treatment effect favouring homeopathy: its overall 
designation would be ‘low quality’ rather than ‘very low quality’.  
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currently unknown if other potential flaws, connected with deficiencies of external validity for example 231 
[10], might impinge on overall quality ratings of the trials we examined. 232 
 233 
In classifying each of MVHT and RoB, we considered some domains of assessment to have lesser 234 
importance than others.  This judgmental approach to the relative importance of domains is consistent 235 
with the Cochrane method of attributing overall RoB per trial [6].  It preserves PRISMA standards of 236 
reporting, and it has successfully identified trials of individualised homeopathy that comprise ‘reliable 237 
evidence’.  Similar dual assessment and analysis will feature in our subsequent systematic review of 238 
placebo-controlled RCTs of non-individualised homeopathy. 239 
 240 
CONCLUSIONS 241 
 242 
The quality appraisal of 32 RCTs of individualised homeopathic treatment, merging the assessments of 243 
MVHT and RoB, identified three trials of ‘high quality’, eight of ‘moderate quality’, 18 of ‘low quality’ 244 
and three of ‘very low quality’.  Since the three ‘high quality’ trials are those that were already identified 245 
as ‘reliable evidence’, there is no change in our main conclusion from previous meta-analysis based on 246 
the best-quality RCTs: the medicines prescribed in individualised homeopathy may have small, specific, 247 
treatment effects. 248 
 249 
ADDITIONAL FILES 250 
 251 
Supplementary file 1: Rank order of 32 trials by overall quality designation, and showing direction of 252 
treatment effect (from meta-analysis data): if reclassifying White (2003) as ‘Uncertain RoB – reliable 253 
evidence’. 254 
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Table 1: Method for merging RoB and MVHT into single overall designation of quality 
Attribute of quality    
RoB MVHT Descriptive criteria for downgrading Downgrading Overall designation 
Low risk Acceptable 
Neither attribute has important flaws 0 High quality 
Uncertain risk** Acceptable 
Uncertain risk Acceptable One attribute is 'uncertain'; the other 
attribute is 'uncertain' or better 
-1 Moderate quality 
Uncertain risk Uncertain 
Uncertain risk Inadequate 
One attribute has important flaws -2 Low quality High risk Acceptable 
High risk Uncertain 
High risk Inadequate Both attributes have important flaws -3 Very low quality 
 
**Includes those trials designated ‘reliable evidence’. 
No trial in the current study was designated ‘low risk of bias’ – see Results. 
 
  
Table 2: Rank order of 32 trials by overall quality designation, and showing direction of treatment effect (from meta-analysis data2) 
 
Ref. First author Year Overall RoB Overall MVHT Downgrading Overall designation Direction of effect 
A5 Bell  2004    Uncertain** Acceptable 0 High quality   Homeopathy 
A19 Jacobs 1994    Uncertain** Acceptable 0 High quality *Homeopathy 
A20 Jacobs 2001    Uncertain** Acceptable 0 High quality   Homeopathy 
A10 Chapman  1999 Uncertain Acceptable -1 Moderate quality   Homeopathy 
A14 Frass 2005 Uncertain Acceptable -1 Moderate quality *Homeopathy 
A23 Jacobs 2005a Uncertain Acceptable -1 Moderate quality  Placebo 
A36 Thompson 2005 Uncertain Acceptable -1 Moderate quality   Homeopathy 
A41 Yakir 2001 Uncertain Acceptable -1 Moderate quality   Homeopathy 
A6 Bonne 2003 Uncertain Uncertain -1 Moderate quality  Placebo 
A11 de Lange de Klerk 1994 Uncertain Uncertain -1 Moderate quality   Homeopathy 
A35 Straumsheim 2000 Uncertain Uncertain -1 Moderate quality  Placebo 
A7 Brien 2011 High Acceptable -2 Low quality  Placebo 
A9 Cavalcanti 2003 High Acceptable -2 Low quality   Homeopathy 
A13 Fisher 2006 High Acceptable -2 Low quality   Homeopathy 
A18 Jacobs 1993 High Acceptable -2 Low quality ---- 
A21 Jacobs 2000 High Acceptable -2 Low quality ---- 
A22 Jacobs 2005b High Acceptable -2 Low quality *Homeopathy 
A24 Jansen 1992 High Acceptable -2 Low quality ---- 
A31 Rastogi (a) 1999 High Acceptable -2 Low quality   Homeopathy 
A31 Rastogi (b) 1999 High Acceptable -2 Low quality  Placebo 
A33 Siebenwirth 2009 High Acceptable -2 Low quality  Placebo 
A38 Weatherley-Jones 2004 High Acceptable -2 Low quality   Homeopathy 
A16 Gaucher 1994 High Uncertain -2 Low quality ---- 
A26 Katz 2005 High Uncertain -2 Low quality ---- 
A30 Naudé 2010 High Uncertain -2 Low quality ---- 
A32 Sajedi 2008 High Uncertain -2 Low quality  Placebo 
A37 Walach 1997 High Uncertain -2 Low quality ---- 
A40 Whitmarsh 1997 High Uncertain -2 Low quality   Homeopathy 
A25 Kainz 1996 Uncertain Inadequate -2 Low quality   Homeopathy 
A1 Andrade 1991 High Inadequate -3 Very low quality ---- 
A34 Steinsbekk 2005 High Inadequate -3 Very low quality ---- 
A39 White 2003 High Inadequate -3 Very low quality ---- 
 
** Reliable evidence. * Homeopathy significantly superior to placebo (P < 0.05)  
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Table 3: Frequency table of MVHT and RoB 
 
 
 
 
** Reliable evidence 
 
  
Number of trials 
Risk of bias 
Totals Uncertain** Uncertain High 
MVHT 
Acceptable 3 5 11 19 
Uncertain 0 3 6 9 
Inadequate 0 1 3 4 
Totals 3 9 20 32 
  
 
 
 
 
 
 
Table 4: Frequency table of MVHT and direction of treatment effect 
 
 
 
 
 
  
Number of trials 
Direction of treatment effect 
Totals 
Favours homeopathy Favours placebo 
MVHT 
Acceptable 12 4 16 
Uncertain 2 3 5 
Inadequate 1 0 1 
Totals 15 7 22 
  
 
 
 
 
 
 
Table 5: Frequency table of RoB and direction of treatment effect 
 
 
 
 
** Reliable evidence 
  
Number of trials 
Direction of treatment effect 
Totals 
Favours homeopathy Favours placebo 
RoB 
Uncertain** 3 0 3 
Uncertain 6 3 9 
High 6 4 10 
Totals 15 7 22 
  
Table 6: Sensitivity analysis by overall quality designation 
Ref. First author Year Overall designation OR [95%CI] 
Pooled OR [95% 
CI] for N trials 
N trials 
included 
P for N 
trials  
A5 Bell 2004 High quality 1.77 [0.66, 4.72] 
1.98 [1.16, 3.38] 3 0.013 A19 Jacobs 1994 High quality 2.22 [1.00, 4.94] 
A20 Jacobs 2001 High quality 1.84 [0.63, 5.36] 
A10 Chapman 1999 Moderate quality 1.98 [0.72, 5.49] 
1.64 [1.24, 2.17] 11 < 0.001 
A14 Frass 2005 Moderate quality 3.13 [1.10, 8.86] 
A23 Jacobs 2005a Moderate quality 0.80 [0.25, 2.57] 
A36 Thompson 2005 Moderate quality 1.94 [0.66, 5.64] 
A41 Yakir 2001 Moderate quality 5.50 [0.96, 31.62] 
A6 Bonne 2003 Moderate quality 0.87 [0.28, 2.73] 
A11 de Lange de Klerk 1994 Moderate quality 1.67 [0.96, 2.89] 
A35 Straumsheim 2000 Moderate quality 0.80 [0.34, 1.90] 
A7 Brien 2011 Low quality 0.86 [0.16, 4.47] 
1.53 [1.22, 1.91] 22 < 0.001 
A9 Cavalcanti 2003 Low quality 3.50 [0.55, 22.30] 
A13 Fisher 2006 Low quality 1.33 [0.34, 5.30] 
A22 Jacobs 2005b Low quality 3.84 [1.06, 13.90] 
A31 Rastogi (a) 1999 Low quality 1.36 [0.45, 4.10] 
A31 Rastogi (b) 1999 Low quality 0.53 [0.17, 1.69] 
A33 Siebenwirth 2009 Low quality 0.49 [0.07, 3.65] 
A38 Weatherley-Jones 2004 Low quality 1.47 [0.62, 3.47] 
A32 Sajedi 2008 Low quality 0.55 [0.09, 3.34] 
A40 Whitmarsh 1997 Low quality 1.72 [0.69, 4.34] 
A25 Kainz 1996 Low quality 1.41 [0.45, 4.45] 
 
 Additional File 1: Rank order of 32 trials by overall quality, and showing direction of treatment effect (from meta-analysis data):  if reclassifying 
White (2003) as ‘Uncertain RoB – reliable evidence’ (see also http://www.britishhomeopathic.org/wp-content/uploads/2015/01/BHA-16-Jan-2015.pdf) 
 
Ref. First author Year Overall RoB Overall MVHT Downgrading Overall designation Direction of effect 
A5 Bell  2004    Uncertain** Acceptable 0 High quality   Homeopathy 
A19 Jacobs 1994    Uncertain** Acceptable 0 High quality *Homeopathy 
A20 Jacobs 2001    Uncertain** Acceptable 0 High quality   Homeopathy 
A10 Chapman  1999 Uncertain Acceptable -1 Moderate quality   Homeopathy 
A14 Frass 2005 Uncertain Acceptable -1 Moderate quality *Homeopathy 
A23 Jacobs 2005a Uncertain Acceptable -1 Moderate quality  Placebo 
A36 Thompson 2005 Uncertain Acceptable -1 Moderate quality   Homeopathy 
A41 Yakir 2001 Uncertain Acceptable -1 Moderate quality   Homeopathy 
A6 Bonne 2003 Uncertain Uncertain -1 Moderate quality  Placebo 
A11 de Lange de Klerk 1994 Uncertain Uncertain -1 Moderate quality   Homeopathy 
A35 Straumsheim 2000 Uncertain Uncertain -1 Moderate quality  Placebo 
A7 Brien 2011 High Acceptable -2 Low quality  Placebo 
A9 Cavalcanti 2003 High Acceptable -2 Low quality   Homeopathy 
A13 Fisher 2006 High Acceptable -2 Low quality   Homeopathy 
A18 Jacobs 1993 High Acceptable -2 Low quality ---- 
A21 Jacobs 2000 High Acceptable -2 Low quality ---- 
A22 Jacobs 2005b High Acceptable -2 Low quality *Homeopathy 
A24 Jansen 1992 High Acceptable -2 Low quality ---- 
A31 Rastogi (a) 1999 High Acceptable -2 Low quality   Homeopathy 
A31 Rastogi (b) 1999 High Acceptable -2 Low quality  Placebo 
A33 Siebenwirth 2009 High Acceptable -2 Low quality  Placebo 
A38 Weatherley-Jones 2004 High Acceptable -2 Low quality   Homeopathy 
A16 Gaucher 1994 High Uncertain -2 Low quality ---- 
A26 Katz 2005 High Uncertain -2 Low quality ---- 
A30 Naudé 2010 High Uncertain -2 Low quality ---- 
A32 Sajedi 2008 High Uncertain -2 Low quality  Placebo 
A37 Walach 1997 High Uncertain -2 Low quality ---- 
A40 Whitmarsh 1997 High Uncertain -2 Low quality   Homeopathy 
A39 White 2003    Uncertain** Inadequate -2 Low quality   Homeopathy 
A25 Kainz 1996 Uncertain Inadequate -2 Low quality   Homeopathy 
A1 Andrade 1991 High Inadequate -3 Very low quality ---- 
A34 Steinsbekk 2005 High Inadequate -3 Very low quality ---- 
 
** Reliable evidence. * Homeopathy significantly superior to placebo (P < 0.05) 
